A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC

NCT07726992 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillary-Only Non-muscle-invasive Bladder Cancer

Interventions

DRUG: SHR-1501+BCG
DRUG: Placebo +BCG

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.